Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-directed RNA polymerase I subunit A (POLR1A) is the largest and catalytic subunit of the multimeric RNA polymerase I enzyme complex, which is responsible for the transcription of rDNA into the 47S pre-ribosomal RNA precursor; this process is the first and key step in ribosome biogenesis in eukaryotic cells[1][2][3][4][5]. POLR1A, together with POLR1B/RPA2, forms the enzyme’s core catalytic site and orchestrates transcription initiation, elongation, and termination on ribosomal gene clusters. High POLR1A activity underpins ribosomal RNA synthesis required for cell growth and proliferation, and its dysregulation is linked to several cancers and genetic syndromes, such as Acrofacial dysostosis, Cincinnati type, or congenital leukodystrophies[1][2][3][4]. Pol I inhibitors are in development for oncology indications, targeting the abnormal transcriptional activity of this enzyme in tumor cells[2].
Inhibition of RNA polymerase I-mediated rRNA transcription; Induction of nucleolar stress leading to p53 activation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-directed RNA polymerase I subunit A (POLR1A).